瘤内微生物组由转移部位驱动并与免疫组织病理学参数相关:SHIVA临床试验的辅助研究
该辅助研究对SHIVA01试验中79例乳腺癌、肺癌或结直肠癌患者的淋巴结、肺或肝活检样本行16S rRNA基因测序,发现微生物丰富度、均匀度和β多样性与活检部位相关而非原发肿瘤类型,微生物丰富度与肿瘤浸润淋巴细胞及PD-L1表达呈负相关,低丰富度患者总生存和无进展生存更短。
要点
- 微生物丰富度、均匀度和β多样性与活检部位显著相关,与原发肿瘤类型无关。
- 微生物丰富度与肿瘤浸润淋巴细胞及PD-L1表达(免疫细胞、TPS、CPS)呈负相关。
- 低瘤内微生物丰富度患者的总生存和无进展生存更短。
核心结论
- 活检部位而非原发肿瘤类型与微生物组多样性强烈相关,PD-L1表达和肿瘤浸润淋巴细胞等免疫组织病理学参数与α和β多样性显著相关,支持癌症-微生物组-免疫轴假说。
研究设计与样本
- SHIVA01试验的辅助研究,分析79例乳腺癌、肺癌或结直肠癌患者淋巴结、肺或肝活检样本,行细菌16S rRNA基因测序以表征瘤内微生物组,并评估微生物组组成与临床病理特征及结局的关联。
主要发现
- 微生物丰富度(Chao1指数)、均匀度(Shannon指数)和β多样性(Bray Curtis距离)与活检部位相关(p=0.0001、p=0.03和p<0.0001),与原发肿瘤类型无关(p=0.52、p=0.54和p=0.82)。
- 微生物丰富度与肿瘤浸润淋巴细胞呈负相关(p=0.02),与免疫细胞PD-L1表达呈负相关(p=0.03),与肿瘤比例评分(TPS)评估的PD-L1表达呈负相关(p=0.02),与联合阳性评分(CPS)评估的PD-L1表达呈负相关(p=0.04)。
- β多样性与上述免疫组织病理学参数也相关(p<0.05)。
- 多变量分析中,瘤内微生物丰富度较低的患者总生存较短(p=0.03)且无进展生存较短(p=0.02)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on the role of the microbiota in cancer have accumulated in recent years, with particular interest in intratumoral bacteria. Previous results have shown that the composition of intratumoral microbiome is different depending on the type of primary tumour and that bacteria from the primary tumour could migrate to metastatic sites. METHODS: Seventy-nine patients with breast, lung, or colorectal cancer and available biopsy samples from lymph node, lung, or liver site, treated in the SHIVA01 trial were analysed. We performed bacterial 16S rRNA gene sequencing on these samples to characterise the intratumoral microbiome. We assessed the association between microbiome composition, clinicopathological characteristics, and outcomes. RESULTS: Microbial richness (Chao1 index), evenness (Shannon index) and beta-diversity (Bray Curtis distance) were associated with biopsy site (p = 0.0001, p = 0.03 and p < 0.0001, respectively) but not with primary tumour type (p = 0.52, p = 0.54 and p = 0.82, respectively). Furthermore, microbial richness was inversely associated with tumour-infiltrating lymphocytes (TILs, p = 0.02), and PD-L1 expression on immune cells (p = 0.03), or assessed by Tumor Proportion Score (TPS, p = 0.02) or Combined Positive Score (CPS, p = 0.04). Beta-diversity was also associated with these parameters (p < 0.05). Patients with lower intratumoral microbiome richness had shorter overall survival (p = 0.03) and progression-free survival (p = 0.02) in multivariate analysis. CONCLUSION: Biopsy site, rather than primary tumour type, was strongly associated with microbiome diversity. Immune histopathological parameters such as PD-L1 expression and TILs were significantly associated with alpha and beta-diversity supporting the cancer-microbiome-immune axis hypothesis.
引用
- Hilmi M, Kamal M, Vacher S, et al. Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial. Eur J Cancer. 2023. PMID: 36868056. doi:10.1016/j.ejca.2023.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。